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A B S T R A C T
Objective: In women at risk of developing preeclampsia, we evaluated the use of a digital health platform for
telemonitoring blood pressure and symptoms combined with a minimal antenatal visit schedule.
Study design: A case-control study for women with chronic hypertension, history of preeclampsia, or maternal
cardiac or kidney disease. A care path was designed with reduced visits enhanced with a digital platform
(SAFE@HOME) for daily blood pressure and symptom monitoring starting from 16 weeks of gestation. Home-
measurements were monitored in-hospital by obstetric professionals, taking actions upon alarming results. This
prospective SAFE@HOME group was compared to a retrospective control group managed without self-mon-
itoring.
Main outcome measures: Primary: healthcare consumption (number of antenatal visits, ultrasounds, admissions
and diagnostics), user experiences of the platform. Secondary: maternal and perinatal outcomes.
Results: Baseline characteristics of the SAFE@HOME (n = 103) and control group (n = 133) were comparable.
In the SAFE@HOME group, antenatal visits (mean 13.7 vs 16.0, p < 0.001) and ultrasounds (6.3 vs 7.4,
p = 0.005) were lower compared to the control group. Admissions for hypertension or suspected preeclampsia
were significantly fewer in the SAFE@HOME group (2.9% versus 13.5%, p = 0.004). Telemonitoring partici-
pants were highly satisfied using the platform. No differences were observed for maternal and perinatal out-
comes.
Conclusions: Our care path including blood pressure telemonitoring for women at risk of preeclampsia allows
fewer antenatal visits, ultrasounds and hypertension-related admissions. We observed no differences in perinatal
outcomes. These results suggest that telemonitoring of blood pressure is feasible in a high-risk pregnant popu-
lation and has the potential to profoundly change antenatal care.
1. Introduction
Hypertension in pregnancy is increasingly common, and an im-
portant cause of maternal and neonatal morbidity and mortality, at
short as well as long term [1,2]. Frequent monitoring of blood pressure
(BP), fetal growth, blood and urine during pregnancy is recommended
to early identify and monitor hypertensive disease [3]. Interfering with
daily life, (un)planned visits and hospitalization pose a substantial
burden to patients and care resources [4].
International guidelines from 2013 onwards recommend self-mea-
surements for patients with (gestational) hypertension [5–7]. Recent
research has shown that pregnant women are willing to undertake re-
peated self-measurements for involvement of blood pressure manage-
ment [8–10]. As such, the adoption of digital health has been suggested
to achieve higher-value antenatal care [11].
We developed a digital telemonitoring platform enabling home
blood pressure measurements and preeclampsia symptom reporting
[12]. This redesign of antenatal care, with a predefined minimal visit
schedule and telemonitoring, is anticipated to enhance digital interac-
tion and women’s autonomy while maintaining safety of antenatal care.
Furthermore, telemonitoring might allow less frequent antenatal visits.
It could potentially also lead to more visits as a result of an overload of
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data or questions in contrast. The precise role of digital exchange of
home measurements in pregnancies at increased risk has yet to be es-
tablished.
We evaluated our digital health platform in antenatal care for pa-
tients at increased risk of developing preeclampsia, together with a
newly developed reduced antenatal visit schedule, from 16 weeks ge-
stational age onwards.
2. Methods
2.1. Study population and design
This case-control study was conducted in two perinatal centres in
urban areas in the Netherlands: one university hospital (2500 deliveries
annually, both secondary and tertiary care) and one general teaching
hospital (3000 deliveries annually). The study population consisted
pregnant women with a singleton pregnancy and one (or more) of the
following risk factors for preeclampsia: chronic hypertension, pre-
eclampsia in a prior pregnancy, maternal cardiac disease, or maternal
kidney disease. A prospective group of women, managed with use of the
digital platform, was compared with a retrospective group with iden-
tical risk factors at start of pregnancy, but managed with conventional
care. This study was submitted to the Medical Ethics Committee of the
University Medical Center in Utrecht (17/424). The committee judged
that the Dutch Medical Research Involving Human Subjects Act (WMO)
did not apply to this study.
The SAFE@HOME group consisted of women, who presented with
one of the fore-mentioned risk factors between October 2017 and
December 2018 in our clinics. Eligible candidates for the prospective
study were> 18 years of age, had access to a smartphone or tablet with
Internet connection and could understand Dutch or English language.
Kidney transplant patients and arm circumference> 42 cm (as pre-
scribed by the instructions of the monitor) were considered an exclu-
sion criterion.
The control group consisted of retrospectively selected women with
one of the aforementioned four risk factors at start of pregnancy. After
database search for these risk factors amongst all deliveries between 1
and 1-2015 and 31-12-2016, patients were included in this control
group only if they received antenatal care from intake to delivery in the
same centre. Exclusion criteria were maternal age<18 years and
kidney transplant. Antenatal care in the control group was based on the
Dutch guideline on hypertensive disorders of pregnancy, without use of
home blood pressure measurements [13]. Follow-up visits were
planned once per two weeks, with increased frequency if indicated by
their care provider, depending on the patient’s condition, BP or medi-
cation use. Antihypertensive medication was generally prescribed in
case of blood pressure> 160/> 110 mmHg. Hospitalization was re-
commended in case of preeclampsia, or fetal growth restriction with
indication for daily cardiotocography (pulsatility index of the umbilical
artery> 95th centile).
2.2. Intervention
The digital health platform consisted of the Luscii platform (by
Focuscura, the Netherlands, in collaboration with UMC Utrecht) and
the iHealth Track automated blood pressure monitor, validated for use
in pregnancy [14].
Development of the platform was described before and its use was
found feasible in our hospital setting in a low risk pregnant population
[12]. This study showed good participant compliance and high accu-
racy of the alarm system [12]. Subsequently, telemonitoring with the
platform was offered to patients at risk of preeclampsia from October
2017 onwards. As part of this novel strategy, a uniform care path was
predefined (Fig. 1). We organized 4 multidisciplinary meetings with
obstetricians, internists, cardiologists and nephrologists, nurses and
patients for the development of the schedule. Considering the home-
measurements and symptom scores, they discussed the desired struc-
ture of care, outcome measures of interest and the objective of each
planned clinic and ultrasound visit.
Before start of the study, a local telemonitoring team was set up.
Nurses and midwives of these teams were trained in a 1-h course to 1)
register and instruct new participants to use the monitor and platform
and 2) perform daily monitoring of alerts and subsequent actions.
Obstetricians (in training) were trained how to access the home mea-
surements and to plan future appointments using the predefined sche-
dule.
Women who gave written informed consent were provided access to
the secured platform from 16 weeks gestational age onwards. They
were trained to obtain correct measurements with the iHealth Track.
From study enrolment to delivery date, they were asked to submit a
single blood pressure on weekdays before 10.00AM. In-app or email
reminders were sent automatically at 7.00AM. The blood pressure
measurement was transferred to the app with Bluetooth, and the
pregnant woman could forward it to the platform after manual check. If
blood pressure was raised, participants answered an in-app symptom
checklist, containing 10 yes/no questions for symptoms that occur in
(the development of) preeclampsia as well as general pregnancy
symptoms (Table 1). Uploaded values were visible for both the patient
and the healthcare provider, on a monitoring dashboard in the elec-
tronic health record.
Values exceeding the set threshold values led to alerts on the
monitoring dashboard, reviewed by a member of the telemonitoring
team every weekday at 10.30 AM. Alerts were set for a systolic value
of> 140 mmHg or diastolic> 90 mmHg and/or an increase of
20 mmHg compared to the previous measurement. These thresholds
were chosen as they indicate new-onset of gestational hypertension
following international consensus, but can be altered in the dashboard
to provide individual care [15–17]. For the symptom checklist, the
platform alarmed if ≥1 symptoms were present. Alerts were reviewed
with a protocol of flowcharts taking into account several combinations
of hypertension and symptoms (Supplementary Fig. 1). If needed, the
telemonitoring team would consult the obstetrician and subsequently
contact the participant to advice one of the following: 1) expectant
management or 2) same-day clinical assessment of blood pressure and
symptoms and 3) if necessary with blood/urine analysis, 4) adjustment
of antihypertensive therapy, 5) admission to the antenatal ward, and 6)
induction of labour. To ensure patient safety, all alerts in the dashboard
had to be switched off manually after processing the protocolled steps.
In both study groups therapeutic interventions including induction
of labour or caesarean section were started according to local protocol
based on the Dutch national guideline [13].
2.3. Outcomes and data collection
Primary outcomes were healthcare consumption and user experi-
ences of the digital telemonitoring platform. Secondary outcomes were
maternal and neonatal perinatal outcomes.
For healthcare consumption, the number of antenatal visits, ultra-
sounds for fetal assessment, blood and urinary analysis, medication use
and admissions were extracted from participants’ hospital system.
For user experiences, SAFE@HOME participants were invited to
answer an online survey at 36 weeks of gestation with 10 statements
regarding their experiences with the platform on a 5-point Likert scale.
Derived from the Luscii webportal, the start, duration and frequency
blood pressure and symptom monitoring, as well as number of alerts
and raised readings were recorded.
For maternal and perinatal outcome, pregnancy and delivery data
were recorded and used to compare both groups. Risk factors for pre-
eclampsia in each group and other maternal characteristics were col-
lected at baseline from hospital records. Chronic hypertension, gesta-
tional hypertension, preeclampsia and eclampsia were defined
according to ISSHP criteria [15].
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2.4. Statistical analyses
Given the exploratory nature of this study, no formal sample size
calculation was performed. Continuous outcome variables were re-
presented as means with standard deviations or, if skewed, medians
with interquartile ranges (IQR), and were compared by the Student’s t-
test or Mann-Whitney-U test. Categorical outcome variables were
compared between groups by the chi-square or Fisher’s exact test. P-
values below 0.05 were considered as statistically significant. Statistical
analysis was performed with IBM SPSS version 25.
3. Results
For the SAFE@HOME group, 111 women were found eligible and
invited to participate, of which 109 consented (Fig. 2). During the study
period, 2 participants experienced pregnancy loss< 21 weeks of ge-
station, and 2 were lost to follow-up. Only 2 women (< 2%) were ex-
cluded from the SAFE@HOME strategy and returned to standard care
because they were non-compliant to study instructions. For the final
analysis, 103 participants were included in in the SAFE@HOME group.
In the control group, 133 eligible women were included. Fig. 3 shows
the selection of these 133 participants from retrospective database
search.
Baseline characteristics are shown in Table 2. Maternal age, BMI,
ethnicity, education level and parity were similar between groups, as
were history of hypertensive disorders op pregnancy (HDP) and intake
blood pressure. The distribution of the four risk factors for pre-
eclampsia, as reason for study inclusion, was comparable for pre-
eclampsia in prior pregnancy, chronic hypertension and maternal car-
diac disease. However, more women with kidney disease were included
in the SAFE@HOME group (16.5% vs 4.5%, p = 0.002), as one of the
study centres became a referral centre for kidney disease in pregnancy
during the intervention period.
3.1. Healthcare consumption
Table 3 demonstrates healthcare consumption during pregnancy.
The number of antenatal visits from the first visit to delivery was sig-
nificantly lower in the SAFE@HOME group as compared to the control
group (mean 13.7 [4.1] vs 16.0 [4.0], p < 0.001). The total number of
ultrasound assessments was also significantly lower in the SAFE@
HOME group (mean 6.3 [2.7] vs 7.4 [2.9], p = 0.005). These sig-
nificant reductions were primarily observed between 34 weeks of ge-
station and delivery, which corresponds to the proposed visit schedule
(Fig. 1 and Table 4).
In the SAFE@HOME group, observational admissions for hy-
pertension or diagnosis/exclusion of suspected preeclampsia were sig-
nificantly lower compared to the control group (2.9% vs 13.5% of
Fig. 1. Predefined antenatal visit schedule as part of the intervention for patients at risk for of development of preeclampsia.
Table 1
The ten-question preeclampsia symptom checklist in the telemonitoring plat-
form, to be answered with Yes or No buttons.
• Do you have headaches?• Do you have visual problems?• Do you have a tight, band-like feeling around the upper stomach?• Do you experience severe upper abdominal pain?• Do your fingers feel numb?• Do you feel nauseous?• Do you have ankle, hand or face swelling?• Do you have contractions?• Do you have vaginal fluid loss?• Do you have vaginal bleeding?
Fig. 2. Flow chart of participants enrolled in the SAFE@HOME group.
Fig. 3. Flow chart of participants enrolled in the control group.
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participants, p = 0.004, Table 3). Overall, no significant difference was
found in the number of patients who needed an antenatal admission for
any other obstetric indication (i.e. fetal monitoring, antepartum hae-
morrhage or intravenous treatment for severe hypertension or pre-
eclampsia): 31.1% in SAFE@HOME vs 39.1% in control group,
p = 0.20. The mean number of blood tests for evaluation of hy-
pertension/preeclampsia did not differ between groups.
3.2. User experiences and data on home measurements
The online survey on SAFE@HOME experiences was answered by
51 (49%) participants. Few had difficulties with using the system (4%,
2/51) and instructions regarding the use of the BP monitor and app
were clear to almost all (96%, 49/51) (Supplementary Fig. 2). Daily
measurements took ≤ 5 min for 81% (mean 4.6 min), and 98% (50/51)
could easily perform their routine tasks while using the platform. The
vast majority was satisfied with the use of the app and platform (92%,
47/51) and especially parous participants would recommend it to other
women (96.9% of multiparous vs. 73.7% of nulliparous women).
Telemonitoring participants started their home measurements on
average at 17.9 weeks of gestation (SD 3.9) and continued this for
20.2 weeks (SD 4.0) until delivery (Table 2). During pregnancy, the
median number of uploaded blood pressure measurements per parti-
cipant was 90.0 in total (IQR 68.0–107.0, range 18–201) or 4.5 per
week of telemonitoring (IQR 3.6–5.0, range 0.9–12). The median
compliance rate for all scheduled blood pressure measurements was








Age (years) mean (SD) 33.7 (4.6) 33.1 (4.7) 0.27
Body mass index (kg/m2) mean (SD) 25.2 (4.5) 26.5 (5.75) 0.06
Ethnicity n (%)
Caucasian 82 (79.6) 97 (72.9) 0.23
Mediterranean 14 (13.6) 24 (18.0) 0.36
Afro–Caribbean 4 (3.9) 6 (4.5) 1,00
Other/unknown 3 (2.9) 6 (4.5) 0.74
Education n (%)
Primary school or less 3 (2.9) 2 (1.5) 0.66
High school or less 9 (8.7) 5 (3.8) 0.11
Secondary vocational school 36 (35.0) 44 (33.1) 0.76
Higher professional education 30 (29.1) 48 (36.1) 0.26
University graduate 25 (24.3) 34 (25.6) 0.82
Nulliparity n (%) 31 (30.1) 36 (27.1) 0.61
Smoker n (%) 2 (2.0) 6 (4.6) 0.47
Psychiatric disorder in pregnancy n (%) 7 (6.8) 8 (6.3) 0.84
Prior HDP n (%) 40 (38.8) 68 (51.1) 0.13
Systolic BP at intake (mmHg) mean (SD) 120 (16.9) 122 (17.8) 0.26
Diastolic BP at intake (mmHg) mean (SD) 74 (12.3) 75 (12.8) 0.39
Risk factor for inclusion n (%)
Prior preeclampsia 23 (22.3) 44 (33.1) 0.07
Chronic hypertension 28 (27.2) 45 (33.8) 0.27
Cardiac disease * 35 (34.0) 38 (28.6) 0.37
Kidney disease § 17 (16.5) 6 (4.5) 0.002
Start of telemonitoring Weeks
gestational age
17.9 (3.9) – –
Duration of telemonitoring Weeks 20.2 (4.0) – –
(BP, blood pressure; GA, gestational age; HDP hypertensive disorder of pregnancy).
* e.g. maternal congenital heart disease, arrhythmias, valvular heart disease, aortopathy.
§ e.g. (obstetric) antiphospholipid syndrome, systemic lupus erythematosus, chronic kidney disease.
Table 3
Results of healthcare consumption.
SAFE@HOMEn = 103 Control n = 133 p-value
Total number of visits mean (SD) 13.7 (4.0) 16,0 (4.1) < 0,001
GA 0–26 weeks “ 5.9 (2.5) 6.2 (2.4) 0.23
GA 26–34 weeks “ 4.1 (2.0) 4.5 (2.0) 0.16
GA 34- delivery “ 3.8 (2.0) 5.3 (2.4) < 0,001
Total number of ultrasound assessments mean (SD) 6.3 (2.7) 7.4 (2.9) 0.005
GA 0–26 weeks “ 2.8 (1.5) 3.5 (1.5) < 0.001
GA 26–34 weeks “ 2.7 (1.6) 2.6 (1.7) 0.58
GA 34- delivery “ 0.9 (0.9) 1.1 (1.2) 0.004
≥1 antenatal admissions (for any obstetric indication) n (%) 32 (31.1) 52 (39.1) 0.20
Duration (days) median (IQR) 4.5 (2–11.5) 6 (2–19) 0.50
≥1 antenatal admissions for observation of hypertension or suspected preeclampsia n (%) 3 (2.9) 18 (13.5) 0.004
Duration (days) median (IQR) 2 (2–2) 2.75 (2–4) 0.10
Number of blood tests for hypertension evaluation mean (SD) 2.9 (3.7) 2.5 (3.6) 0.38
(GA, gestational age; PE, preeclampsia).
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3.3. Perinatal outcome
Table 4 shows the pregnancy outcomes in both groups. At delivery,
diagnoses of gestational hypertension, preeclampsia, chronic hy-
pertension without superimposed preeclampsia or normotensive preg-
nancy were similar between groups. Approximately 20% of all parti-
cipants developed preeclampsia, and fetal growth restriction (estimated
fetal weight< 10th centile) occurred in± 10% of all pregnancies
(Table 4). Labour induction was more frequent in the SAFE@HOME
group (56.3 vs 38.3%, p = 0.006). However, hypertension as the main
indication for induction was not significantly different between groups
(56.9 vs 54.9% of inductions, p = 0.99). Planned induction for patients
with cardiac disease was more frequent, although not significant, in the
SAFE@HOME group (16.5 vs 9.0%, p = 0.08). No other differences
were found regarding mode of delivery.
One antepartum fetal death, not related to telemonitoring, occurred
in the SAFE@HOME group, in a woman included because of a history of
preeclampsia. There were no maternal complications. No other serious
adverse events were observed in both groups.
In general, no differences were detected in use of (iv) anti-hy-
pertensive drugs, magnesium sulphate or glucocorticoids for fetal lung
maturation (Table 4). Results were also similar for gestational age at
Table 4
Pregnancy outcomes.
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delivery (mean 38.3 weeks (2.1) vs 38.8 weeks (2.3) p = 0.11), birth
weight< 5th centile (4.9 vs 9.0%, p = 0.22), and admission to neo-
natal intensive care unit (1.9 vs 4.5%, p = 0.47).
4. Discussion
4.1. Main findings
We studied the use of a novel care path with telemonitoring of blood
pressure and preeclampsia symptoms in a high-risk pregnant popula-
tion. Our findings show that this strategy allows a reduced antenatal
visit schedule, with fewer ultrasound assessments and antenatal hy-
pertension-related admissions. However, evaluation was by comparison
with a retrospective group without telemonitoring nor a fixed antenatal
visit schedule. In our sample, no differences were found in adverse
maternal or perinatal outcomes between the two strategies.
4.2. Comparison to the literature and interpretation
The NICE guideline on antenatal care recommends more frequent
blood pressure monitoring for those at risk of HDP and several others
mention self-monitoring as a useful addendum to antenatal care [7,16].
A recent individual patient data meta-analysis of 758 subjects found an
insignificant difference between clinic readings and self-monitored
blood pressure values [17]. Based on this evidence, our threshold for
alerts was set at 140/90 mmHg to be of clinical importance.
Recent literature describes a variety of monitoring strategies for
women with (a higher risk of) hypertension in pregnancy [18–21]. In
general, reduction of antenatal visits with help of out-of-office self-
measurements, as found in our study, are in line with several other
studies. One retrospective study of blood pressure telemonitoring for
diagnosed hypertension in pregnancy showed a reduction of antenatal
visits and admissions [18]. Two case-control studies started blood
pressure self-monitoring in women with diagnosed hypertension,
without telemonitoring but providing written instructions to patients
when to contact the hospital [19,20]. Starting self-monitoring at
30–36 weeks of gestation, fewer visits were required with self-mon-
itoring compared to a retrospective group with traditional care, in both
studies. More importantly, the shift from hospital to home care did not
seem to negatively affect pregnancy outcomes, although study sample
sizes were likely not large enough to determine this [18–20]. One other
prospective study started telemonitoring at start of pregnancy but did
not include a control group for comparison of results [21]. There is
conflicting data on the rate of labour induction in the literature. As for
our study, induction of labour was more frequently started in the
SAFE@HOME group, however hypertension as the main reason for
induction of labour was similar between groups.
Our study differed from the described studies on several points. Our
population of women, at risk of preeclampsia but without complica-
tions in first trimester, started telemonitoring early in pregnancy (mean
17.9 weeks of gestation) instead of starting at 30–36 weeks. Also, a
symptom checklist was included within the platform. This combination
proved to be beneficial for the full course of pregnancy. Absence of both
hypertension and symptoms requires no further action, while symptoms
in case of hypertension indicate need for evaluation.
4.3. Strengths and limitations
Our digital platform is one of the first to combine both blood
pressure and symptom reporting, used with a reduced visit schedule.
Prior to the study start, we validated the blood pressure monitor and
carried out a feasibility study to test the Bluetooth-connected platform
[12,14]. Eligible candidates were willing to participate in tele-
monitoring, which is reflected in the high consent rate. Only 2/109
participants were transferred to standard care because of non-com-
pliance.
A limitation of this study is the comparison to a retrospective con-
trol group, which is likely to have caused selection bias. The greater
proportion of included women with kidney disease in the SAFE@HOME
group adds to heterogeneity, because of the specific etiology of kidney
disease as an increased risk factor for preeclampsia. This might limit
generalizability of results.
Our study was not powered adequately to draw conclusions re-
garding adverse perinatal outcomes and therefore, future studies with
substantial sample size would be needed.
Lastly, the studied strategy is a combination of both a digital health
platform for remote monitoring and a reduced visit schedule. It is un-
known whether the implementation of either of these components of
the intervention individually would result in a similar effect on
healthcare consumption and adverse outcomes.
4.4. Future implications
Our results imply that use of telemonitoring at home of blood
pressure and preeclampsia symptoms in high risk pregnancies allows
for fewer antenatal visits, notably after 34 weeks of gestation. The use
of home measurements did not lead to an increase in health care con-
sumption. Increased experience and compliance of obstetric care pro-
fessionals to the new strategy may enhance the reduction of care use in
the future.
Several implications of blood pressure telemonitoring in pregnancy
still need evaluation. Before widespread use of telemonitoring, more
evidence is needed from larger prospective studies. Studied groups
should include both women at risk of hypertension or preeclampsia at
start of pregnancy, as well as those with established gestational hy-
pertension or mild preeclampsia [22]. Current knowledge gaps include
the safety and impact of telemonitoring on (early) detection and/or
prediction of complications as well as its effect on subsequent inter-
ventions as medication use and hypertension control, induction of la-
bour, optimal administration of corticosteroids.
In general, digital health has the potential to have profound cost-
saving effects because of the decline in visits, admissions, travel time,
and work absence [23]. Women of reproductive age are interested in
digital health, as shown by their frequent use of smartphones and
pregnancy apps [24,25]. In future digital health studies of in preg-
nancy, use of healthcare services should be assessed too. Alongside its
medical effects, cost-effectiveness must be evaluated before im-
plementation of digital health in pregnancy care. The latter may also
contribute to reimbursement of digital care [26,27].
5. Conclusion
Use of a digital health platform for blood pressure and symptom
telemonitoring allows for fewer antenatal visits and ultrasound assess-
ments in pregnancies at risk of preeclampsia. In this study there was no
increase of adverse maternal and neonatal outcomes as compared to the
control group. Larger prospective studies on telemonitoring in preg-
nancy are needed for evaluation of perinatal safety outcomes and cost-
effectiveness.
Contribution to authorship
JFH, ATL, JCT and MNB designed the study. JFH, ATL, JJH and
MNB were responsible for the acquisition and interpretation of the data.
JFH and MNB drafted the manuscript. All authors edited and revised
the manuscript. All authors have read and approved the final version of
the manuscript.
Details of ethics approval
This study was submitted to the Medical Ethics Committee of the
University Medical Center in Utrecht (17/424). The committee judged
J.F.M. van den Heuvel, et al. Pregnancy Hypertension 22 (2020) 30–36
35
that the Dutch Medical Research Involving Human Subjects Act (WMO)
did not apply to this study.
Funding
This research was funded by the e-Health Citrien Program of the
Dutch Federation of University Medical Centers (Nederlandse Federatie
van Universitair Medische Centra, NFU).
Declaration of Competing Interest
The authors declare that they have no known competing financial
interests or personal relationships that could have appeared to influ-
ence the work reported in this paper.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.preghy.2020.07.006.
References
[1] J.A. Hutcheon, S. Lisonkova, K.S. Joseph, Epidemiology of pre-eclampsia and the
other hypertensive disorders of pregnancy, Best Pract. Res. Clin. Obstet. Gynaecol.
25 (4) (2011) 391–403.
[2] T.K.J. Groenhof, G.A. Zoet, A. Franx, R.T. Gansevoort, M.L. Bots, H. Groen,
E.T. LelyPREVEND Group, Trajectory of cardiovascular risk factors after hy-
pertensive disorders of pregnancy, Hypertension 73 (1) (2019) 171–178.
[3] NICE Clinical Guideline 133 Hypertension in pregnancy: diagnosis and manage-
ment (updated in 2019) [10-07-2019].
[4] W. Stevens, T. Shih, D. Incerti, T.G.N. Ton, H.C. Lee, D. Peneva, G.A. Macones,
B.M. Sibai, A.B. Jena, Short-term costs of preeclampsia to the United States health
care system, Rep. Major Impact 217 (3) (2017) 237–248.E16.
[5] T.G. Pickering, N.H. Miller, G. Ogedegbe, L.R. Krakoff, N.T. Artinian, D. Goff, Call to
action on use and reimbursement for home blood pressure monitoring: a joint
scientific statement from the American Heart Association, American Society Of
Hypertension, and Preventive Cardiovascular Nurses Association, Hypertension 52
(1) (2008) 10–29.
[6] American College of Obstetricians and Gynecologists, Task Force on Hypertension
in Pregnancy. Hypertension in pregnancy. Report of the American College of
Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet.
Gynecol. 122(5) (2013) 1122–1131 PMID: 24150027.
[7] L.A. Magee, A. Pels, M. Helewa, E. Rey, P. von Dadelszen, Diagnosis, evaluation,
and management of the hypertensive disorders of pregnancy: executive summary, J.
Obstet. Gynaecol. Can. 36 (2014) 416–441.
[8] J.A. Hodgkinson, K.L. Tucker, C. Crawford, S.M. Greenfield, C. Heneghan,
L. Hinton, K. Khan, L. Locock, L. Mackillop, C. McCourt, M. Selwood, R.J. McManus,
Is self monitoring of blood pressure in pregnancy safe and effective? BMJ 349
(2014) g6616.
[9] L. Hinton, K.L. Tucker, S.M. Greenfield, J.A. Hodgkinson, L. Mackillop, C. McCourt,
T. Carver, C. Crawford, M. Glogowska, L. Locock, M. Selwood, K.S. Taylor, R.J.
McManus, Blood pressure self-monitoring in pregnancy (BuMP) feasibility study; a
qualitative analysis of women's experiences of self-monitoring, BMC Pregnancy
Childbirth 17(1) (2017) 427.
[10] L.A. Magee, P. von Dadelszen, S. Chan, A. Gafni, A. Gruslin, M. Helewa, S. Hewson,
E. Kavuma, S.K. Lee, A.G. Logan, D. McKay, J.M. Moutquin, A. Ohlsson, E. Rey, S.
Ross, J. Singer, A.R. Willan, M.E. Hannah, F.T. Group, Women's views of their ex-
periences in the CHIPS (Control of Hypertension in Pregnancy Study) Pilot Trial,
Hypertens Pregnancy 26(4) (2007) 371–387.
[11] V.G. Woo, T. Lundeen, S. Matula, A. Milstein, Achieving higher-value obstetrical
care, Am. J. Obstet. Gynecol. 250 (2017;216(3):) e1–e14.
[12] J.F.M. van den Heuvel, S.S. Kariman, W.W. van Solinge, A. Franx, A.T. Lely,
M.N. Bekker, SAFE@HOME – feasibility study of a telemonitoring platform com-
bining blood pressure and preeclampsia symptoms in pregnancy care, Eur. J.
Obstet. Gynecol. Reprod. Biol. 240 (2019) 226–231.
[13] Dutch Society of Obstetrics and Gynaecology; Hypertensive disorders or pregnancy,
2011 [accessed 10-07-2019].
[14] J.F.M. Van Den Heuvel, A.T. Lely, A. Franx, M.N. Bekker, Validation of the iHealth
Track and Omron HEM-9210T automated blood pressure devices for use in preg-
nancy, Pregnancy Hypertens. 15 (2019) 37–41.
[15] A.L. Tranquilli, G. Dekker, L. Magee, J. Roberts, B.M. Sibai, W. Steyn, et al., The
classification, diagnosis and management of the hypertensive disorders of preg-
nancy: a revised statement from the ISSHP, Pregnancy Hypertens. 4 (2) (2014)
97–104.
[16] NICE Clinical Guideline 62 Antenatal care for uncomplicated pregnancies, 2019
[05-05-2019].
[17] K.L. Tucker, C. Bankhead, J. Hodgkinson, N. Roberts, R. Stevens, C. Heneghan,
É. Rey, C. Lo, M. Chandiramani, R.S. Taylor, R.A. North, A. Khalil, K. Marko,
J. Waugh, M. Brown, C. Crawford, K.S. Taylor, L. Mackillop, R.J. McManus, How do
home and clinic blood pressure readings compare in pregnancy? Hypertension 72
(3) (2018) 686–694.
[18] D. Lanssens, S. Vonck, V. Storms, I.M. Thijs, L. Grieten, W. Gyselaers, The impact of
a remote monitoring program on the prenatal follow-up of women with gestational
hypertensive disorders, Eur. J. Obstet. Gynecol. Reprod. Biol. 223 (2018) 72–78.
[19] E. Kalafat, K. Leslie, A. Bhide, B. Thilaganathan, A. Khalil, Pregnancy outcomes
following home blood pressure monitoring in gestational hypertension, Pregnancy
Hypertens. 18 (2019) 14–20.
[20] H. Perry, E. Sheehan, B. Thilaganathan, A. Khalil, Home blood-pressure monitoring
in a hypertensive pregnant population, Ultrasound Obstet. Gynecol. 51 (4) (2018)
524–530.
[21] K.L. Tucker, K.S. Taylor, C. Crawford, J.A. Hodgkinson, C. Bankhead, T. Carver,
E. Ewers, M. Glogowska, S.M. Greenfield, L. Ingram, L. Hinton, K.S. Khan,
L. Locock, L. Mackillop, C. McCourt, A.M. Pirie, R. Stevens, R.J. McManus, Blood
pressure self-monitoring in pregnancy: examining feasibility in a prospective cohort
study, BMC Pregnancy Childbirth 17 (1) (2017) 442.
[22] G. Dougall, M. Franssen, K.L. Tucker, et al., Blood pressure monitoring in high-risk
pregnancy to improve the detection and monitoring of hypertension (the BUMP 1
and 2 trials): protocol for two linked randomised controlled trials, BMJ Open 10
(2020) e034593. doi:10.1136/bmjopen-2019-034593.
[23] S.J. Iribarren, K. Cato, L. Falzon, P.W. Stone, What is the economic evidence for
mHealth? A systematic review of economic evaluations of mHealth solutions, PLoS
One 12 (2) (2017) e0170581.
[24] J.F. van den Heuvel, T.K. Groenhof, J.H. Veerbeek, W.W. van Solinge, A.T. Lely,
A. Franx, et al., eHealth as the next-generation perinatal care: an overview of the
literature, J. Med. Internet Res. 20 (6) (2018) e202.
[25] J.M. Radin, E.J. Topol, S.R. Steinhubl, A digital toolkit for improved maternal
health, Lancet 392(10153) (2018).
[26] E.R. Dorsey, E.J. Topol, State of Telehealth, N. Engl. J. Med. 375 (2) (2016)
154–161.
[27] E.J. Topol, A decade of digital medicine innovation, Sci. Transl. Med. 11(498)
(2019).
J.F.M. van den Heuvel, et al. Pregnancy Hypertension 22 (2020) 30–36
36
